3D Systems Corporation — FY2020 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2020; quarterly figures below identify the fourth quarter. 3D Systems sells 3D printers, materials, software, and manufacturing and healthcare services. In August 2020, it refocused its strategy on higher-value additive manufacturing applications and reorganized around Healthcare and Industrial markets. The company continued to report as one operating segment.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $557.2 million | $636.4 million |
| Gross profit / margin | $223.4 million / 40.1% | $280.5 million / 44.1% |
| Operating loss | $119.0 million | $57.1 million |
| Net loss attributable to 3D Systems | $149.6 million; $1.27 per diluted share | $69.9 million; $0.61 per diluted share |
| Cash from (used in) operations | $(20.1) million | $31.6 million |
- Healthcare revenue rose 9.1% to $245.4 million, primarily on stronger dental sales. Industrial revenue fell 24.2% to $311.9 million. Software revenue declined 12.7% to $86.0 million.
- Fourth-quarter revenue was $172.7 million, up 2.6% from $168.2 million a year earlier. The quarter recorded operating income of $0.7 million and a net loss of $19.8 million, compared with an operating loss of $4.7 million and net loss of $4.7 million in Q4 2019.
- Cash and cash equivalents were $75.0 million at year-end, down from $133.7 million. The company used $20.1 million in operating cash, spent $13.6 million on capital expenditures, repaid $26.8 million of debt, and received $24.7 million net from its at-the-market share issuance program.
- At December 31, 2020, term debt was $21.4 million and revolving-facility availability was $62.0 million; the company reported compliance with credit covenants. In January 2021, it used proceeds from the Cimatron sale to repay the remaining term debt.
- Year-end total assets were $733.1 million and total liabilities were $302.3 million. The company reported $430.7 million of stockholders’ equity.
Changes, outlook, risks, and unusual items
- Revenue declined 12.4%, with COVID-19-related customer shutdowns and reduced activity weighing most heavily on results in the first half. Management said activity partially recovered in Q3 and that Q4 revenue exceeded the prior-year quarter.
- Gross margin fell four percentage points, reflecting lower volume and under-absorbed production overhead. A $12.4 million end-of-life inventory charge also weighed on gross profit; management reported that excluding this charge, gross margin would have been 42.3%.
- Operating expenses included a $48.3 million non-cash goodwill impairment charge for EMEA. Net loss also reflected $24.4 million of interest and other expense, including divestiture-related losses and withholding taxes.
- The August restructuring plan targeted nearly 20% workforce reduction and approximately $80 million of annualized cost savings by the end of 2021, plus a further approximately $20 million dependent on potential divestitures. The company incurred $20.1 million of restructuring costs in 2020 and expected additional charges as actions were completed. These are targets, not guaranteed results.
- On January 1, 2021, the company completed the sale of Cimatron and GibbsCAM for approximately $64.2 million, after adjustments and excluding $9.2 million of cash transferred to the buyer. It terminated its ATM program in January. These post-year-end events were not reflected as completed transactions in FY2020.
- Principal risks include uncertain COVID-19 effects, uneven hardware sales cycles, customer concentration (one customer represented 13% of 2020 revenue), supply-chain dependence, restructuring execution, and foreign-exchange exposure. U.S. government investigations into potential export-control and sanctions issues remained ongoing; the company disclosed grand jury subpoenas and continuing cooperation. Its Air Force administrative agreement and independent monitoring remained in effect.
- Management identified two material weaknesses in financial reporting controls: controls over certain non-standard contracts and review of internally prepared closing reports and analyses. The auditor issued an adverse opinion on internal control effectiveness, while giving an unqualified opinion on the financial statements. Management was implementing remediation; timing and effectiveness were not assured. The filing provides no formal revenue or earnings guidance.
Important facts for investors to verify
- Whether the company achieves the targeted cost savings and completes any additional planned divestitures without disrupting operations.
- Progress in remediating the material weaknesses and whether subsequent filings report effective internal controls.
- Updates and potential financial consequences of the export-control, sanctions, and government-contracting investigations and administrative agreement.
- Cash generation, liquidity, covenant compliance, and the use of Cimatron sale proceeds following repayment of term debt.
- Whether the Q4 recovery continues, particularly in Industrial markets, and how revenue concentration and end-of-life inventory affect future margins.